Photodynamic therapy of non melanoma skin cancer murine model by topical application of a novel mTHPC liposomal formulation

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Alexandratou, E en
dc.contributor.author Kyriazi, M en
dc.contributor.author Trebst, T en
dc.contributor.author Grafe, S en
dc.contributor.author Yova, D en
dc.date.accessioned 2014-03-01T02:51:09Z
dc.date.available 2014-03-01T02:51:09Z
dc.date.issued 2007 en
dc.identifier.issn 16057422 en
dc.identifier.uri http://hdl.handle.net/123456789/35408
dc.relation.uri http://www.scopus.com/inward/record.url?eid=2-s2.0-36248970198&partnerID=40&md5=0e76b38e03107f63ad7b44b47c3b08df en
dc.subject Liposomal formulation en
dc.subject mTHPC en
dc.subject Non melanoma skin cancer en
dc.subject Photodynamic therapy en
dc.subject Topical application en
dc.subject.other Diseases en
dc.subject.other Liposomes en
dc.subject.other Oncology en
dc.subject.other Photosensitizers en
dc.subject.other Skin en
dc.subject.other Energy doses en
dc.subject.other Liposomal formulations en
dc.subject.other Melanoma skin carcinomas en
dc.subject.other Photodynamic efficacy en
dc.subject.other Topical applications en
dc.subject.other Photodynamic therapy en
dc.title Photodynamic therapy of non melanoma skin cancer murine model by topical application of a novel mTHPC liposomal formulation en
heal.type conferenceItem en
heal.identifier.secondary 66320V en
heal.publicationDate 2007 en
heal.abstract Photodynamic therapy (PDT) has been used in the treatment of various skin diseases including non melanoma skin carcinomas (NMSC). However, until now there are no publications concerning the efficacy of PDT after topical application of mTHPC. Although topical photosensitizer application presents many advantages over systemic drug administration, ALA-induced protoporphyrin IX is the only sensitizer topically used so far. In the present study photodynamic efficacy of the highly potent sensitizer meso-tetra(hydroxyphenyl)chlorin (mTHPC), supplied in a novel liposome formulation is investigated after topical application in hairless SKH-HR1 mice, bearing non melanoma skin carcinomas. The drug was applied topically for drug - light interval of 4 hours. The fluence rates were 100 and 50 mW/cm2 and two total energy doses, 10 J/cm2 and 100 J/cm2 were studied in groups of 5 animals. Three PDT sessions were performed in each animal, once every 7 days. The final evaluation of PDT effects was performed 14 days after the 3rd PDT treatment by measuring the geometrical characteristics of tumors. The groups treated with 100 mW/cm2 presented a higher complete tumor remission than the group of 50 mW/cm2 but an unusual high mortality. In the group of 50 mW/cm2 and 100 J/cm2, although the complete tumor remission percentage is poor, the tumor growth rate was decreased. No lesion, papilloma, or tumor was observed in the treated area even six months after tumor remission. Furthermore tumours up to 7 mm were achieved to be treated, indicating that this novel mTHPC formulation could be used for deeper and not only superficial carcinomas or lesions. © 2007 SPIE-OSA. en
heal.journalName Progress in Biomedical Optics and Imaging - Proceedings of SPIE en
dc.identifier.volume 6632 en

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record